Delayed Australian S.E. 10:34:59 2024-04-18 pm EDT 5-day change 1st Jan Change
0.034 AUD +3.03% Intraday chart for Respiri Limited 0.00% +13.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Respiri Limited - Shareholder/Analyst Call
Respiri Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Respiri Limited Announces Executive Changes CI
Respiri Signs Deal to Integrate Echo IQ’s Cardiovascular Technology to Remote Monitoring System; Shares Fall 4% MT
Respiri Limited Appoints Tom Takubo as Non-Executive Director CI
Transcript : Respiri Limited - Shareholder/Analyst Call
Respiri Limited Announces Resignation of Brian Leedman as Non-Executive Director CI
Respiri Limited Secures Two Additional Healthcare Provider Contract CI
Australian Bourse Halts Trading in Respiri’s Securities MT
Respiri Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Transcript : Respiri Limited - Special Call
Respiri Completes Access Manages Services Acquisition MT
Respiri Completes AU$3 Million Share Purchase Plan MT
Transcript : Respiri Limited - Shareholder/Analyst Call
Respiri Extends Closing Date of Share Purchase Plan MT
Respiri Signs Marketing Agreement for Wheezo Device with Fi-Med Management MT
Transcript : Access Managed Services LLC, Respiri Limited - M&A Call
Respiri Limited Appoints Brian Leedman as Non-Executive Director CI
Respiri Appoints Chief Commercial Officer for US Market MT
Respiri Limited Appoints William Sigsbee as Chief Commercial Officer for the US Market CI
Transcript : Respiri Limited - Special Call
Respiri Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Respiri Forms US Advisory Board to Advance Wheezo Program as Part of Standard of Care; Shares Slump 9% MT
Respiri Limited Forms Medical Advisory Board CI
Respiri's wheezo Program Now Included in Michigan Children’s Hospital's Standard Asthma Care for Children; Shares Fall 6% MT
Chart Respiri Limited
More charts
Respiri Limited is an Australia-based e-health software as a service company that supports respiratory health management. It is engaged in research, development and commercialization of medical devices, and the development of mobile health applications. Its Wheezo technology is a breath sensor (medical device) that works with the respiri mobile applications (patient user interface) to record and track wheeze. Wheezo is a smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals. Wheezo is used to detect and record abnormal breath sounds (continuous adventitious breath sounds) in the windpipe (trachea), reported as WheezeRate in adults and children for more than two years. It also offers connected care solutions for management of people living with chronic diseases.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RSH Stock
  4. News Respiri Limited
  5. Respiri : to Start Selling Wheezo Devices Across Australia; Shares Surge 14%